Letrozole (Femara) early and late responses to treatment
收藏官方服务：
资源简介：
Letrozole (Femara) early and late responses to treatment
应用场景：
创建时间：
2010-07-28
相关数据集
Low and High Dose Progestins Elicit Distinct Breast Cancer Biology. Homo sapiens
An incomplete understanding of dose-dependent progesterone receptor (PR) biology has led to the suboptimal exploitation of PR as a therapeutic target. While hormone replacement therapies (HRT) contain
NIAID Data Ecosystem90
Antitumor Activity of Z-endoxifen in Aromatase Inhibitor-Sensitive and Resistant Estrogen Receptor-Positive Breast Cancer. Antitumor Activity of Z-endoxifen in Aromatase Inhibitor-Sensitive and Resistant Estrogen Receptor-Positive Breast Cancer
The overarching goal of this study was to explore the antitumor activity of Z-endoxifen, a tamoxifen metabolite, with first-line endocrine therapies tamoxifen and letrozole in the letrozole-sensitive
NIAID Data Ecosystem40
Additional file 8 of Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Additional file 8. List of 660 genes regulated by tamoxifen treatment in the MCF7LR tumors compared to letrozole-treated MCF7LR tumors.
Figshare2020-05-20 更新40
SET ER/PR - A robust 18-gene Predictor for Sensitivity to Endocrine Therapy for Metastatic Breast Cancer. SET ER/PR - A robust 18-gene Predictor for Sensitivity to Endocrine Therapy for Metastatic Breast Cancer
There is clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diag
NIAID Data Ecosystem90
Tamoxifen_Based_乳腺癌女性生殖系统超声队列研究数据
本数据集为基于超声的队列研究数据，研究他莫昔芬对乳腺癌女性生殖系统的影响。研究在巴格达三家肿瘤中心开展，纳入255例雌激素受体阳性乳腺癌患者（140例绝经前、115例绝经后），患者术后接受他莫昔芬辅助治疗至少3个月。数据记录患者年龄、绝经状态、合并症及用药情况，共包含1个文件。
海数据40
